The European Medicines Agency confirmed, on Monday, that it will send a team of experts to Russia next April to review clinical trials and produce the Russian “Sputnik V” vaccine.
The head of the health threats and vaccination strategy at the agency, Marco Cavalieri, said in an interview with the Italian channel “Rai3”, that “in addition to the Russian vaccine, the German (Curevac) and the American (Novavax) are currently being examined by the European medical authorities.”
He added: “With regard to the Russian vaccine, there is a periodic examination, so we will review all the data when it is collected in order for it to be approved faster .. In April, we will conduct an examination in Russia, whether in terms of production or clinical trials, then we will try to understand at what time we will have. All data necessary for the possible approval of this vaccine at the end. “
The head of the Coronavirus Working Group announced, earlier, that “the European Agency may approve the Russian vaccine no later than next May.”
In turn, the head of the “Lazio” metropolitan area, Nicola Zingaretti, said last Saturday that “an agreement will be concluded within a few days to conduct scientific experiments for the vaccine (Sputnik V) at the Lazaro Spallanzani National Institute for Infectious Diseases in Rome.”
Last February, the scientific journal “Lancet” published the results of the third phase of clinical trials of the “Sputnik V” vaccine, confirming its high efficacy and safety, noting that “the vaccine showed at that time high rates of efficacy, immunity and safety, which reached 91.6%, and that it provides protection.” Complete against severe cases of new corona virus infection. “
More than 52 countries expressed their approval to use the Russian “Sputnik V” vaccine, knowing that it ranks second in the world in terms of the number of approvals obtained by government regulators.